Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Kezar Life Sciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
KZR
Nasdaq
8731
https://kezarlifesciences.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Kezar Life Sciences Inc
13 Best Penny Stocks to Buy According to Billionaire Ken Griffin
- Apr 8th, 2024 9:38 pm
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
- Apr 8th, 2024 8:01 pm
From Pennies to Fortunes: 3 Stocks Set to Make Millionaires
- Mar 27th, 2024 8:30 pm
Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026
- Mar 16th, 2024 10:56 am
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
- Mar 14th, 2024 8:01 pm
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
- Feb 28th, 2024 9:01 pm
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
- Feb 26th, 2024 11:30 pm
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
- Feb 25th, 2024 7:12 pm
3 Penny Stocks Poised for an Unbelievable 1,000% Jump
- Feb 2nd, 2024 10:37 am
Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth
- Dec 18th, 2023 1:51 pm
Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
- Nov 21st, 2023 9:01 pm
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 13th, 2023 9:01 pm
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
- Oct 24th, 2023 4:30 pm
12 Best Penny Stocks to Buy Under $1
- Oct 23rd, 2023 2:08 pm
Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce
- Oct 4th, 2023 1:32 pm
Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer
- Oct 3rd, 2023 8:10 pm
Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia
- Sep 20th, 2023 10:30 pm
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
- Aug 31st, 2023 8:01 pm
Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
- Aug 10th, 2023 8:01 pm
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Aug 4th, 2023 8:03 pm
Scroll